Published in Arthritis Res Ther on September 02, 2010
Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis. Arthritis Rheumatol (2015) 1.84
Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol (2014) 1.58
Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol (2013) 1.43
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum (2011) 1.22
Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol (2012) 1.03
IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis (2012) 0.98
Genetics of scleroderma: implications for personalized medicine? BMC Med (2013) 0.92
Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) (2013) 0.88
The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis (2013) 0.84
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol (2011) 0.83
Right bundle branch block: a predictor of mortality in early systemic sclerosis. PLoS One (2013) 0.82
Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum (2013) 0.80
Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. Chest (2013) 0.79
Predictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. PLoS One (2011) 0.79
Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohort. Semin Arthritis Rheum (2011) 0.78
Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. Clin Rheumatol (2013) 0.78
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Ann Am Thorac Soc (2016) 0.78
Genetic architecture of human fibrotic diseases: disease risk and disease progression. Front Pharmacol (2013) 0.76
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS One (2016) 0.75
A Probabilistic Graphical Model for Individualizing Prognosis in Chronic, Complex Diseases. AMIA Annu Symp Proc (2015) 0.75
Pulmonary involvement in systemic sclerosis: A clinical profile. Lung India (2016) 0.75
A prediction model for progressive disease in systemic sclerosis. RMD Open (2015) 0.75
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther (2016) 0.75
Immunosuppression for interstitial lung disease in systemic sclerosis - novel insights and opportunities for translational research. J Cell Commun Signal (2012) 0.75
CCL-2 in the Circulation Predicts Long-term Progression of Interstitial Lung Disease in Early Systemic Sclerosis Patients: Data from Two Independent Cohorts. Arthritis Rheumatol (2017) 0.75
Standardisation of spirometry. Eur Respir J (2005) 48.20
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J (2005) 7.58
Standardisation of the measurement of lung volumes. Eur Respir J (2005) 7.48
Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis (2007) 4.88
Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol (1995) 4.11
Autoantibodies in systemic sclerosis. Semin Arthritis Rheum (2005) 3.55
Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med (2008) 3.19
Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum (1988) 2.93
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Coping with rheumatoid arthritis pain: catastrophizing as a maladaptive strategy. Pain (1989) 2.44
Iron-deficiency anaemia: its effect on transfer factor for the lung (diffusiong capacity) and ventilation and cardiac frequency during sub-maximal exercise. Clin Sci (1972) 2.41
Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med (2008) 2.22
Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum (1994) 2.11
Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med (2005) 1.93
Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med (1993) 1.91
Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum (2009) 1.88
Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum (2001) 1.87
Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol (2005) 1.67
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum (1996) 1.54
Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol (2007) 1.46
Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum (2007) 1.33
Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum (1985) 1.21
Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum (2009) 1.15
Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol (2003) 1.14
Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) (2003) 1.14
African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest (1998) 1.14
Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger? Postgrad Med J (1991) 1.11
Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis (2003) 1.10
Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am J Med (1987) 1.04
Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol (2005) 1.01
Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore) (1984) 1.00
Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum (2006) 0.99
Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol (2009) 0.96
Serial changes in scleroderma and idiopathic interstitial lung disease. Arch Intern Med (1973) 0.94
Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol (2009) 0.93
A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol (1997) 0.91
Systemic sclerosis mortality in the United States: 1999-2002 implications for patient care. J Clin Rheumatol (2007) 0.90
Serial pulmonary function in systemic sclerosis. Am J Med (1982) 0.89
Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum (2001) 0.88
Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis. Chest (1994) 0.87
Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J (2009) 0.82
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum (2008) 13.08
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol (2005) 9.25
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
Disruption of GW bodies impairs mammalian RNA interference. Nat Cell Biol (2005) 5.52
A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell (2002) 5.34
The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies. RNA (2003) 4.40
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet (2010) 3.58
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation. J Cell Sci (2004) 3.31
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Gene and pathway-based second-wave analysis of genome-wide association studies. Eur J Hum Genet (2010) 3.03
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 2.80
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet (2011) 2.54
Surgical team behaviors and patient outcomes. Am J Surg (2008) 2.51
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum (2009) 2.50
Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet (2010) 2.44
Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol (2012) 2.43
Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum (2013) 2.42
The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum (2013) 2.40
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2009) 2.26
A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum (2007) 2.24
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol (2014) 1.99
Formation of GW bodies is a consequence of microRNA genesis. EMBO Rep (2006) 1.92
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91
Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics (2007) 1.90
Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum (2001) 1.87
Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis (2009) 1.84
Small interfering RNA-mediated silencing induces target-dependent assembly of GW/P bodies. Mol Biol Cell (2007) 1.83
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum (2011) 1.78
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum (2011) 1.70
The C-terminal half of human Ago2 binds to multiple GW-rich regions of GW182 and requires GW182 to mediate silencing. RNA (2009) 1.69
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis (2007) 1.69
Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol (2004) 1.69
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol (2005) 1.66
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum (2005) 1.64
Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum (2008) 1.64
New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Rheumatol (2014) 1.64
The role of GW/P-bodies in RNA processing and silencing. J Cell Sci (2007) 1.63
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol (2014) 1.62
Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev (2012) 1.60
Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol (2002) 1.57
Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum (2006) 1.57
The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther (2003) 1.56
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.53
Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing. J Cell Sci (2008) 1.53
Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial. J Pediatr (2004) 1.53
Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum (2007) 1.51
Morphea in adults and children cohort III: nested case-control study--the clinical significance of autoantibodies in morphea. JAMA Dermatol (2013) 1.51
DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol (2011) 1.51
Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet (2011) 1.49
Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum (2006) 1.47
Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis (2006) 1.47
Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther (2008) 1.47
Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. J Pediatr (2012) 1.46
A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet (2008) 1.43
Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol (2013) 1.43
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum (2009) 1.43
Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet (2010) 1.43
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum (2005) 1.42
Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis. Ann Rheum Dis (2009) 1.42
Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. J Rheumatol (2009) 1.42
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis (2011) 1.41
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet (2012) 1.41
Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum (2010) 1.40
Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther (2007) 1.40
Accuracy of the computer-aided surgical simulation (CASS) system in the treatment of patients with complex craniomaxillofacial deformity: A pilot study. J Oral Maxillofac Surg (2007) 1.39
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) (2006) 1.39
Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun (2009) 1.38